The Indian pharmaceutical sector is keeping the M&A fire burning with six deals concluded last month, up from eight in the January-March period. The list includes Jubilant Organosys' $255m acquisition of US-based DRAXIS Health and the $218m buyout of Dabur...
If you use an RSS reader, you can subscribe to a feed of all future entries tagged 'DowPharma'. [What is this?]